Teva Climbs as CEO Sees Robust Growth After Allergan Deal

Updated on
  • CEO Vigodman says generic-drug purchase to close ‘at any time’
  • Adjusted earnings, sales estimates exceed analysts forecasts

Teva Surges on Robust Outlook, Allergan Deal

Teva Pharmaceutical Industries Ltd. surged the most in a year after Israel’s biggest company presented investors with a rosy picture of the drugmaker’s future, starting with the imminent approval of its $40.5 billion deal with Allergan Plc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.